Branded Generic Pharmaceuticals
Steffen Saltofte, CEO
Gary Hughes, CFO
Chairman of the Board
Acino is a leader in advanced drug delivery technologies specialising in modified release oral forms and oral dispersible forms for which it also holds patents. As a partner of pharmaceutical companies worldwide, Acino supplies finished in-house developed products and/or provides customised one-stop solutions from product development and registration to contract manufacturing, packaging and logistics. Under the brand "Acino Switzerland", Acino markets Swiss-quality medicines in fast-growing emerging economies in the Middle East, Africa, Ukraine and the CIS Region (Commonwealth of Independent States) including Russia, and Latin America.
On December 12, 2013, Pharma Strategy Partners GmbH, an indirect subsidiary of Nordic Capital Fund VII and its co-investor Avista Capital Partners, successfully completed its public tender offer for Acino Holding AG. The Acino shares was consequently delisted from the stock exchange. Nordic Capital acquired Acino due to its unique combination of local footprint and Swiss origin, with the aim to further grow the company through selective add-on acquisitions and in-licensing deals.
In April 2018, Nordic Capital’s 2008 vintage fund, Fund VII completed the transfer of its remaining nine unlisted portfolio companies including Acino, to a continuation vehicle, Nordic Capital CV1 or "CV1". Fund VII’s original term expired in December 2017 and by this transaction, Nordic Capital took the opportunity to maximise the value creation potential of these nine companies, providing them with active support and fresh capital over an additional five-year holding period under continued Nordic Capital management.
EUR 420 million
Nordic Capital Fund VII, Nordic Capital CV1